E Fund Management Co. Ltd. Acquires 771 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

E Fund Management Co. Ltd. grew its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 4.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 17,627 shares of the biopharmaceutical company’s stock after purchasing an additional 771 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Dynavax Technologies were worth $225,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Smartleaf Asset Management LLC lifted its position in Dynavax Technologies by 463.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 2,034 shares in the last quarter. US Bancorp DE grew its stake in shares of Dynavax Technologies by 291.4% during the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,034 shares during the last quarter. Capital Performance Advisors LLP acquired a new stake in shares of Dynavax Technologies in the third quarter valued at approximately $45,000. GAMMA Investing LLC raised its position in Dynavax Technologies by 55.1% in the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock worth $52,000 after purchasing an additional 1,457 shares during the last quarter. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new position in Dynavax Technologies during the 4th quarter worth $71,000. Institutional investors own 96.96% of the company’s stock.

Analysts Set New Price Targets

DVAX has been the subject of several research reports. HC Wainwright reissued a “buy” rating and issued a $31.00 target price on shares of Dynavax Technologies in a research note on Friday, February 21st. StockNews.com upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Monday, February 24th. William Blair reissued an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 21st. Finally, The Goldman Sachs Group lowered shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and reduced their target price for the company from $15.00 to $12.00 in a research note on Tuesday, February 11th.

Dynavax Technologies Stock Performance

DVAX stock opened at $14.40 on Monday. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. Dynavax Technologies Co. has a twelve month low of $9.74 and a twelve month high of $14.63. The business’s fifty day moving average is $13.01 and its 200-day moving average is $12.22. The company has a market cap of $1.79 billion, a P/E ratio of 80.00 and a beta of 1.23.

Dynavax Technologies (NASDAQ:DVAX) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.05. The firm had revenue of $72.03 million for the quarter, compared to analysts’ expectations of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. Equities research analysts forecast that Dynavax Technologies Co. will post 0.32 EPS for the current year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.